EA200101268A1 - Способ тиазола, фармацевтические препараты для ингибирования протеинкиназ и способы их применения - Google Patents
Способ тиазола, фармацевтические препараты для ингибирования протеинкиназ и способы их примененияInfo
- Publication number
- EA200101268A1 EA200101268A1 EA200101268A EA200101268A EA200101268A1 EA 200101268 A1 EA200101268 A1 EA 200101268A1 EA 200101268 A EA200101268 A EA 200101268A EA 200101268 A EA200101268 A EA 200101268A EA 200101268 A1 EA200101268 A1 EA 200101268A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- modulate
- cell proliferation
- pharmaceutical preparations
- preparations containing
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 102000001253 Protein Kinase Human genes 0.000 title abstract 2
- 108060006633 protein kinase Proteins 0.000 title abstract 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000004663 cell proliferation Effects 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- WKXCZMFWXZRMEZ-UHFFFAOYSA-N 1,3-thiazole-2,4-diamine Chemical class NC1=CSC(N)=N1 WKXCZMFWXZRMEZ-UHFFFAOYSA-N 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 201000003142 neovascular glaucoma Diseases 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13781099P | 1999-06-04 | 1999-06-04 | |
| PCT/US2000/015188 WO2000075120A1 (fr) | 1999-06-04 | 2000-06-02 | Diaminothiazoles et leur utilisation pour inhiber les proteines kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200101268A1 true EA200101268A1 (ru) | 2002-06-27 |
Family
ID=22479135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200101268A EA200101268A1 (ru) | 1999-06-04 | 2000-06-02 | Способ тиазола, фармацевтические препараты для ингибирования протеинкиназ и способы их применения |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US6620828B2 (fr) |
| EP (1) | EP1181283B1 (fr) |
| JP (1) | JP2003501420A (fr) |
| KR (1) | KR20020015333A (fr) |
| CN (1) | CN1359380A (fr) |
| AP (1) | AP2001002341A0 (fr) |
| AT (1) | ATE288424T1 (fr) |
| AU (1) | AU778071B2 (fr) |
| BG (1) | BG106276A (fr) |
| BR (1) | BR0011585A (fr) |
| CA (1) | CA2371158A1 (fr) |
| CZ (1) | CZ20014213A3 (fr) |
| DE (1) | DE60017894T2 (fr) |
| EA (1) | EA200101268A1 (fr) |
| EE (1) | EE200100659A (fr) |
| ES (1) | ES2234628T3 (fr) |
| HR (1) | HRP20020008A2 (fr) |
| HU (1) | HUP0202897A3 (fr) |
| IL (1) | IL146094A0 (fr) |
| IS (1) | IS6183A (fr) |
| MA (1) | MA25530A1 (fr) |
| MX (1) | MXPA01012483A (fr) |
| NO (1) | NO20015045L (fr) |
| NZ (1) | NZ514881A (fr) |
| OA (1) | OA11959A (fr) |
| PE (1) | PE20010211A1 (fr) |
| PL (1) | PL352714A1 (fr) |
| SK (1) | SK17302001A3 (fr) |
| SV (1) | SV2002000096A (fr) |
| UA (1) | UA71971C2 (fr) |
| UY (1) | UY26190A1 (fr) |
| WO (1) | WO2000075120A1 (fr) |
| YU (1) | YU85601A (fr) |
| ZA (1) | ZA200108291B (fr) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020150921A1 (en) * | 1996-02-09 | 2002-10-17 | Francis Barany | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
| CA2306082A1 (fr) * | 1997-10-27 | 1999-05-06 | Agouron Pharmaceuticals, Inc. | Composes de 4-amino-thiazol-2-y substitues comme inhibiteurs cdks |
| US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US20040226056A1 (en) * | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| ES2391550T3 (es) | 1999-04-15 | 2012-11-27 | Bristol-Myers Squibb Company | Inhibidores cíclicos de la proteína tirosina quinasa |
| EP1347971B1 (fr) | 2000-12-21 | 2006-03-01 | Bristol-Myers Squibb Company | Inhibiteurs thiazolyl des tyrosine kinases de la famille tec |
| US6756374B2 (en) | 2001-01-22 | 2004-06-29 | Hoffmann-La Roche Inc. | Diaminothiazoles having antiproliferative activity |
| UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| MXPA03011196A (es) * | 2001-06-08 | 2004-10-28 | Cytovia Inc | 3-aril-5-aril-[1,2,4]-oxadiazoles sustituidos y analogos. |
| CA2474322A1 (fr) * | 2002-01-25 | 2003-07-31 | Kylix Pharmaceuticals B.V. | (thia-/oxa-/pyra) zoles substitues 4(hetero-) aryle pour inhibition de tie-2 |
| US6818663B2 (en) * | 2002-05-17 | 2004-11-16 | Hoffmann-La Roches | Diaminothiazoles |
| ATE375342T1 (de) | 2002-08-02 | 2007-10-15 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren |
| US8450302B2 (en) | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| TW200416029A (en) * | 2002-11-01 | 2004-09-01 | Takeda Chemical Industries Ltd | Agent for preventing or treating neuropathy |
| WO2004074283A1 (fr) * | 2003-02-21 | 2004-09-02 | Pfizer Inc. | Derives d'amino-thiazole substitues par n-heterocyclyle en tant qu'inhibiteurs de la proteine kinase |
| US7078419B2 (en) | 2003-03-10 | 2006-07-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cytokine inhibitors |
| SI3889142T1 (sl) | 2003-04-11 | 2022-10-28 | Ptc Therapeutics, Inc. | Spojine 1,2,4-oksadiazol benzojske kisline in njihova uporaba za zatiranje nesmiselne ter zdravljenje bolezni |
| WO2004092217A1 (fr) * | 2003-04-17 | 2004-10-28 | Pfizer Inc. | Structure cristalline de complexes du domaine kinase du recepteur du facteur de croissance endothelial vasculaire (vegfrkd) et de ligands et leurs procedes d'utilisation |
| EP1644323B1 (fr) * | 2003-07-07 | 2015-03-18 | Georgetown University | Inhibiteurs d'histone desacetylase et leurs procedes d'utilisation |
| CA2536954C (fr) | 2003-08-29 | 2012-11-27 | Exelixis, Inc. | Modulateurs c-kit et leurs procedes d'utilisation |
| WO2005037235A2 (fr) * | 2003-10-16 | 2005-04-28 | Imclone Systems Incorporated | Inhibiteurs du recepteur 1 du facteur de croissance du fibroblaste et methodes therapeutiques associees |
| EP1709019B1 (fr) * | 2004-01-12 | 2007-08-08 | Applied Research Systems ARS Holding N.V. | Dérivés de thiatole et leur utilisation |
| WO2005108370A1 (fr) * | 2004-04-16 | 2005-11-17 | Ajinomoto Co., Inc. | Composés du benzène |
| US7211576B2 (en) | 2004-04-20 | 2007-05-01 | Hoffmann-La Roche Inc. | Diaminothiazoles |
| CA2573413C (fr) * | 2004-07-12 | 2010-02-09 | Merck & Co., Inc. | Inhibiteurs de l'histone desacetylase |
| AU2006251157B2 (en) | 2005-05-24 | 2011-09-01 | Merck Serono Sa | Thiazole derivatives and use thereof |
| JP5290751B2 (ja) * | 2005-05-24 | 2013-09-18 | メルク セローノ ソシエテ アノニム | チアゾール誘導体及びそれらの使用 |
| SI2395002T1 (sl) | 2005-11-08 | 2014-10-30 | Vertex Pharmaceuticals Incorporated | Farmacevtski sestavek, vsebujoč heterociklični modulator prenašalcev z ATP-vezavno kaseto |
| AU2012244242B2 (en) * | 2005-12-28 | 2015-05-21 | Vertex Pharmaceuticals Incorporated | 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis |
| CA2635760C (fr) * | 2005-12-28 | 2014-07-15 | Vertex Pharmaceuticals Incorporated | Modulateurs de transporteurs a cassette liant l'atp |
| BRPI0706621A2 (pt) * | 2006-01-18 | 2011-04-05 | Amgen Inc | composto, composição farmacêutica, métodos para tratar um distúrbio mediado por quinase em um mamìfero e para tratar um distúrbio relacionado com a proliferação em um mamìfero, e , uso do composto |
| CN101384568B (zh) * | 2006-02-15 | 2012-12-12 | 雅培制药有限公司 | 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用 |
| US8748627B2 (en) * | 2006-02-15 | 2014-06-10 | Abbvie Inc. | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| SG170819A1 (en) | 2006-03-30 | 2011-05-30 | Ptc Therapeutics Inc | Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith |
| WO2008003770A1 (fr) | 2006-07-07 | 2008-01-10 | Boehringer Ingelheim International Gmbh | Dérivés d'hétéroaryle substitués par phényle et leur utilisation en tant qu'agents antitumoraux |
| US7879856B2 (en) | 2006-12-22 | 2011-02-01 | Rigel Pharmaceuticals, Inc. | Diaminothiazoles useful as Axl inhibitors |
| JP5497633B2 (ja) | 2007-05-09 | 2014-05-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｃｆｔｒのモジュレーター |
| JP2010531850A (ja) * | 2007-07-02 | 2010-09-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化合物 |
| CL2008001943A1 (es) | 2007-07-02 | 2009-09-11 | Boehringer Ingelheim Int | Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes. |
| CA2692713A1 (fr) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Modulateurs heterocycliques de pkb |
| WO2009011871A2 (fr) * | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazoles modulateurs de l'activité de pkb |
| AU2008335440B2 (en) | 2007-12-07 | 2013-11-07 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| WO2009073757A1 (fr) | 2007-12-07 | 2009-06-11 | Vertex Pharmaceuticals Incorporated | Formes solides d'acide 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-méthylpyridin-2-yl)benzoïque |
| JP2011506454A (ja) * | 2007-12-13 | 2011-03-03 | グラクソスミスクライン エルエルシー | チアゾールおよびオキサゾールキナーゼ阻害薬 |
| US8299099B2 (en) | 2008-02-28 | 2012-10-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as CFTR modulators |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| US8778929B2 (en) | 2008-09-29 | 2014-07-15 | Boehringer Ingelheim International Gmbh | Substituted heteroaryl inhibitors of B-RAF |
| CN102281875B (zh) | 2009-01-16 | 2017-09-22 | 里格尔药品股份有限公司 | 预防、治疗或应对转移癌的使用axl抑制剂的组合疗法 |
| EP2492269A4 (fr) * | 2009-10-19 | 2013-08-07 | Taisho Pharmaceutical Co Ltd | Dérivé de l'aminothiazole |
| EP2552907B1 (fr) | 2010-03-26 | 2014-10-22 | Boehringer Ingelheim International GmbH | Pyridyltriazoles |
| WO2011117381A1 (fr) | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | Inhibiteurs de kinase b-raf |
| WO2011127241A2 (fr) | 2010-04-07 | 2011-10-13 | Vertex Pharmaceuticals Incorporated | Compositions pharmaceutiques de l'acide 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yle) cyclopropane carboxamido)-3-méthylpyridin-2-yle) benzoïque et leur administration |
| US8710055B2 (en) | 2010-12-21 | 2014-04-29 | Boehringer Ingelheim International Gmbh | Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| WO2013161919A1 (fr) * | 2012-04-26 | 2013-10-31 | 小野薬品工業株式会社 | COMPOSÉ INHIBITEUR DE Trk |
| BR112015019921A2 (pt) | 2013-02-19 | 2017-07-18 | Ono Pharmaceutical Co | composto inibidor de trk |
| GB201309333D0 (en) * | 2013-05-23 | 2013-07-10 | Agency Science Tech & Res | Purine diones as WNT pathway modulators |
| WO2015073231A1 (fr) | 2013-11-12 | 2015-05-21 | Vertex Pharmaceuticals Incorporated | Procédé de préparation de compositions pharmaceutiques pour le traitement de maladies à médiation assurée par le cftr |
| US9873677B2 (en) | 2014-03-06 | 2018-01-23 | Ptc Therapeutics, Inc. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
| WO2016081556A1 (fr) | 2014-11-18 | 2016-05-26 | Vertex Pharmaceuticals Incorporated | Procédé pour effectuer une chromatographie liquide haute performance pour un test à haut rendement |
| CN108348527A (zh) | 2015-10-30 | 2018-07-31 | Ptc医疗公司 | 用于治疗癫痫的方法 |
| CA3036245C (fr) * | 2016-09-13 | 2021-07-20 | Arbutus Biopharma Corporation | Composes de chromane-8-carboxamide substitues et analogues de ceux-ci, et procedes les utilisant |
| CN111233786B (zh) * | 2020-02-04 | 2021-11-26 | 中国人民解放军军事科学院军事医学研究院 | 含五元杂环的苯磺酰胺类化合物及其制备方法和用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE273062C (de) | 1912-04-19 | 1914-04-20 | Deylen Sohn Firma | Vorrichtung zum Schränken von Plattenzündspänen |
| AU558132B2 (en) | 1981-05-27 | 1987-01-22 | Labatt Brewing Co. Ltd. | Malt sterilisation with hydrogen peroxide |
| US4994479A (en) | 1985-04-03 | 1991-02-19 | Yamanouchi Pharmaceutical Co., Ltd. | Phenylene derivatives and anti-allergic use thereof |
| US5409930A (en) * | 1991-05-10 | 1995-04-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| CA2130196A1 (fr) | 1992-03-24 | 1993-09-30 | Jose Luis Castro Pineiro | Derives de la benzodiazepine |
| US5631156A (en) | 1994-06-21 | 1997-05-20 | The University Of Michigan | DNA encoding and 18 KD CDK6 inhibiting protein |
| WO1996014843A2 (fr) | 1994-11-10 | 1996-05-23 | Cor Therapeutics, Inc. | Compositions pharmaceutiques a base de pyrazole, agissant comme inhibiteurs des proteines kinases |
| ATE197300T1 (de) | 1995-02-02 | 2000-11-15 | Smithkline Beecham Plc | Indolderivate als 5-ht rezeptorantagoniste |
| US5710173A (en) | 1995-06-07 | 1998-01-20 | Sugen, Inc. | Thienyl compounds for inhibition of cell proliferative disorders |
| WO1997003967A1 (fr) | 1995-07-22 | 1997-02-06 | Rhone-Poulenc Rorer Limited | Composes aromatiques substitues et leur utilisation pharmaceutique |
| US5705499A (en) | 1995-10-06 | 1998-01-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | 8-arylalkyl- and 8-arylheteroalkyl-5,11-dihydro-6H-dipyrido 3,2-B:2',3'-e! 1!diazepines and their use in the treatment of HIV-1 infection |
| US5733920A (en) | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
| US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| DE69734149T2 (de) | 1996-03-15 | 2006-07-06 | Astrazeneca Ab | Cinoline derivate und verwendung als heilmittel |
| ATE211740T1 (de) | 1996-06-27 | 2002-01-15 | Pfizer | Substituierte indazolderivate |
| IL128642A0 (en) | 1996-09-04 | 2000-01-31 | Pfizer | Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| CA2306082A1 (fr) * | 1997-10-27 | 1999-05-06 | Agouron Pharmaceuticals, Inc. | Composes de 4-amino-thiazol-2-y substitues comme inhibiteurs cdks |
| SK6252000A3 (en) | 1997-11-04 | 2001-11-06 | Pfizer Prod Inc | Indazole bioisostere replacement of catechol in therapeutically active compounds |
| HUP0100330A3 (en) | 1997-11-04 | 2002-03-28 | Pfizer Prod Inc | Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors, compositions containing them and their use |
| US6040321A (en) * | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| ES2237919T4 (es) * | 1998-06-18 | 2007-05-01 | Bristol-Myers Squibb Company | Inhibidores aminotiazol sustituidos con carbono de quinasas dependientes de ciclina. |
| PT1117659E (pt) | 1998-09-29 | 2004-04-30 | Wyeth Corp | Cianoquinolinas substituidas como inibidores de tirosina-quinases de proteinas |
-
2000
- 2000-02-06 UA UA2001129215A patent/UA71971C2/uk unknown
- 2000-06-02 ES ES00942660T patent/ES2234628T3/es not_active Expired - Lifetime
- 2000-06-02 AT AT00942660T patent/ATE288424T1/de not_active IP Right Cessation
- 2000-06-02 EP EP00942660A patent/EP1181283B1/fr not_active Expired - Lifetime
- 2000-06-02 CN CN00808440A patent/CN1359380A/zh active Pending
- 2000-06-02 OA OA1200100321A patent/OA11959A/en unknown
- 2000-06-02 YU YU85601A patent/YU85601A/sh unknown
- 2000-06-02 SV SV2000000096A patent/SV2002000096A/es unknown
- 2000-06-02 PE PE2000000553A patent/PE20010211A1/es not_active Application Discontinuation
- 2000-06-02 AU AU57254/00A patent/AU778071B2/en not_active Ceased
- 2000-06-02 AP APAP/P/2001/002341A patent/AP2001002341A0/en unknown
- 2000-06-02 NZ NZ514881A patent/NZ514881A/en unknown
- 2000-06-02 CA CA002371158A patent/CA2371158A1/fr not_active Abandoned
- 2000-06-02 DE DE60017894T patent/DE60017894T2/de not_active Expired - Fee Related
- 2000-06-02 EE EEP200100659A patent/EE200100659A/xx unknown
- 2000-06-02 UY UY26190A patent/UY26190A1/es not_active Application Discontinuation
- 2000-06-02 PL PL00352714A patent/PL352714A1/xx not_active Application Discontinuation
- 2000-06-02 CZ CZ20014213A patent/CZ20014213A3/cs unknown
- 2000-06-02 EA EA200101268A patent/EA200101268A1/ru unknown
- 2000-06-02 BR BR0011585-1A patent/BR0011585A/pt not_active IP Right Cessation
- 2000-06-02 JP JP2001501601A patent/JP2003501420A/ja not_active Abandoned
- 2000-06-02 MX MXPA01012483A patent/MXPA01012483A/es not_active Application Discontinuation
- 2000-06-02 IL IL14609400A patent/IL146094A0/xx unknown
- 2000-06-02 HU HU0202897A patent/HUP0202897A3/hu unknown
- 2000-06-02 SK SK1730-2001A patent/SK17302001A3/sk unknown
- 2000-06-02 KR KR1020017015384A patent/KR20020015333A/ko not_active Application Discontinuation
- 2000-06-02 WO PCT/US2000/015188 patent/WO2000075120A1/fr not_active Application Discontinuation
-
2001
- 2001-02-15 US US09/783,584 patent/US6620828B2/en not_active Expired - Fee Related
- 2001-10-09 ZA ZA200108291A patent/ZA200108291B/xx unknown
- 2001-10-17 NO NO20015045A patent/NO20015045L/no not_active Application Discontinuation
- 2001-11-29 IS IS6183A patent/IS6183A/is unknown
-
2002
- 2002-01-02 MA MA26465A patent/MA25530A1/fr unknown
- 2002-01-03 BG BG106276A patent/BG106276A/bg unknown
- 2002-01-04 HR HR20020008A patent/HRP20020008A2/hr not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200101268A1 (ru) | Способ тиазола, фармацевтические препараты для ингибирования протеинкиназ и способы их применения | |
| EA200200120A1 (ru) | Соединения индазола, фармацевтические препараты для ингибирования протеинкиназ и способы их применения | |
| TWI262914B (en) | Compounds and pharmaceutical compositions for inhibiting protein kinases | |
| EA200200768A1 (ru) | Соединения индазола, фармацевтические композиции и методы модуляции или ингибирования клеточной пролиферации | |
| EA199900021A1 (ru) | Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы | |
| EA200500811A1 (ru) | 2-(1h-индазол-6-иламино)бензамидные соединения как ингибиторы протеинкиназ, полезные для лечения офтальмологических заболеваний | |
| MXPA06001193A (es) | Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibir la proliferacion celular. | |
| BR0108025A (pt) | Compostos de amida, sal farmaceuticamente aceitável de um metabólito farmaceuticamente ativo do composto, composição farmacêutica para modular ou inibir a atividade de um receptor de proteìna cinase, método de tratamento de uma condição doentia de mamìferos mediada pela atividade de proteìna cinase e método para modular ou inibir a atividade de um receptor de proteìna cinase | |
| EA199900022A1 (ru) | Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы | |
| DE69738949D1 (de) | Chinolincarboxamide als tnf-inhibitoren und als pde-iv inhibitoren | |
| ATE265456T1 (de) | 2-amino-6-anilino-purine und deren verwendung als arzneimittel | |
| EA200200473A1 (ru) | Ингибиторы тирозинкиназы | |
| ATE354372T1 (de) | Verwendung von mif-antagonisten zur krebstherapie | |
| DE69426334T2 (de) | Parenterales Busulfan zur Behandlung von malignen Krankheiten | |
| HUP0002427A2 (hu) | Leptin mint tumorsejt proliferációt gátló hatóanyag és alkalmazása | |
| FR2736915B1 (fr) | Variants de la proteine p53 et utilisations therapeutiques | |
| MXPA03001189A (es) | Compuestos de pirazol-tiazol, composiciones farmaceuticas que los contienen y su uso para inhibir las cinasas dependientes de ciclinas. | |
| MXPA03001452A (es) | Hidroximino-fluorenos heterociclicos y su uso para la inhibicion de las proteinas cinasas. | |
| DE69814691D1 (de) | Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten | |
| TH75180B (th) | สารประกอบอินดาโซลและองค์ประกอบทางเภสัชภัณฑ์ในการยับยั้งโปรตีนไคเนสและวิธีใช้ประโยชน์ | |
| BR0109570A (pt) | Compostos compreendendo uma parte especìfica de célula alvo e uma parte citotóxica, e uma parte mediadora capaz de reconhecer uma molécula especìfica de célula alvo e uma segunda parte citotóxica, molécula de ácido nucleico isolada, método para fabricar um composto, vetor para expressar em uma célula hospedeira, um composto, ou uma parte deste, célula hospedeira, composição farmacêutica, uso de um composto, e método para tratar um paciente tendo células alvo a serem destruìdas | |
| TH140338A (th) | สารประกอบอินดาโซลและองค์ประกอบทางเภสัชภัณฑ์ในการยับยั้งโปรตีนไคเนสและวิธีใช้ประโยชน์ | |
| UY26547A1 (es) | Compuestos de amida y composiciones farmacéuticas para inhibir proteinquinasas, y su modo de empleo |